Ms. Pearce brings over 30 years of commercial
experience and track record of success across global
markets
DUBLIN, July 9, 2024
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today
announced that Samantha Pearce,
Senior Vice President (SVP), Europe and International, has been promoted to
Chief Commercial Officer (CCO) effective August 1, 2024.
Ms. Pearce joined Jazz as SVP, Europe and International, in 2020, and brings
more than 30 years of commercial experience in the pharmaceutical
industry. Since joining Jazz, she has instilled a commitment to a
high-performance culture, growing Jazz's commercial brands and
harnessing the potential of Jazz's European and International
business to provide transformative medicines for patients in more
than 50 countries. In her role as Chief Commercial Officer, she
will be responsible for strategy and execution for Jazz's
commercial business across all global markets and will be based in
the U.S.
"Sam is an inspiring leader with an established track record of
effectively scaling commercial operations to achieve
transformational growth and accelerated patient access to medicines
across geographies," said Renée Galá, President and Chief Operating
Officer, Jazz Pharmaceuticals. "Her
remarkable talent for unifying teams around a shared vision and
cultivating a culture of performance and innovation will
significantly enhance our global commercial business, and I am
thrilled to welcome Sam to this newly created role."
"I am delighted to be stepping into the role of CCO and look
forward to leading the combined commercial organization as we
continue to scale. I am deeply invested in Jazz's mission and
purpose to help patients and remain focused on our commitment to
deliver sustainable growth and enhanced value as an innovative
global biopharmaceutical company," said Ms. Pearce. "I have had the
privilege of leading Jazz's Europe
and International organization since 2020 and look forward to
continuing to partner closely with talented Jazz colleagues to
unlock the potential of our business and deliver innovative,
life-changing medicines for people with serious diseases."
From March 2010 to December 2019, Ms. Pearce held general management
positions across an increasing breadth of global markets with
Celgene Corporation, most recently as vice president and general
manager of international markets. Prior to that, from August 2002 to March
2010, she served in commercial management positions at
AstraZeneca plc, culminating in her role as director of specialist
care. Prior to August 2002, she
worked for DuPont Pharmaceuticals. Ms. Pearce received a B.Sc. from
Birmingham University, U.K. and an
M.B.A. from Cranfield University, U.K.
About Jazz Pharmaceuticals
Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma
company whose purpose is to innovate to transform the lives of
patients and their families. We are dedicated to developing
life-changing medicines for people with serious diseases — often
with limited or no therapeutic options. We have a diverse portfolio
of marketed medicines, including leading therapies for sleep
disorders and epilepsy, and a growing portfolio of cancer
treatments. Our patient-focused and science-driven approach powers
pioneering research and development advancements across our robust
pipeline of innovative therapeutics in oncology and neuroscience.
Jazz is headquartered in Dublin, Ireland with research
and development laboratories, manufacturing facilities and
employees in multiple countries committed to serving patients
worldwide. Please visit www.jazzpharmaceuticals.com for
more information.
Contacts:
Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
Media:
Kristin
Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
View original content to download
multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-promotes-samantha-pearce-to-chief-commercial-officer-302191420.html
SOURCE Jazz Pharmaceuticals plc